Click here to visit A New Era in Anticoagulation for AF and VTE Multimedia series, a valuable ‘one stop’ resource for the media, providing engaging content and educational insights into SPAF and VTE
Read more >
New Phase III data for afatinib* and nintedanib* to be presented at the ASCO 2013 Annual Meeting (American Society of Clinical Oncology)
Read more >
Tiotropium Respimat® is effective in symptomatic asthma patients irrespective of their age, allergic status, smoking status and bronchodilator response.
Read more >
Providing an overview of Regulatory Authorities’ assessment of Pradaxa®
Read more >
This infographic shows the economic burden of venous thromboembolism (VTE)
Read more >
For Non-US, Non-UK & Non-Canadian Media Only Released on 26.03.2013
Read more >
For Non-US, Non-UK & Non-Canadian Media Only Released on 11.03.2013
Read more >
Interim Phase III results in HIV patients co-infected with hepatitis C
Read more >
Tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status
Read more >
Press release announcing a positive recommendation for olodaterol
Read more >
First patients enrolled into Phase III interferon-free trial & SOUND-C3 results
Read more >
New data from our investigational HCV portfolio will be presented at The Liver MeetingTM 2012 in Boston
Read more >
Providing further info on the novel oral anticoagulant, Pradaxa®
Read more >
Safe and effective long-term stroke prevention with Pradaxa®: Results from RE-LY® and RELY-ABLE®
Read more >
FOR NON-US/UK AUDIENCES ONLY Released on 08.11.2012
Read more >
FOR NON-US/UK AUDIENCES ONLY Supplement on importance of long-term clinical data
Read more >
FOR NON-US/UK AUDIENCES ONLY Released on 06.11.2012
Read more >
FOR NON-US/UK AUDIENCES ONLY Released on 05.11.2012
Read more >
FOR NON-US/UK AUDIENCES ONLY Announcing the long-term RELY-ABLE® clinical trial data for Pradaxa®, presented at the AHA Scientific Sessions, 2012.
Read more >
This infographic demonstrates the risk of stroke for people with atrial fibrillation (AF)
Read more >
FOR NON-US/UK AUDIENCES ONLY Released on 31.10.2012
Read more >
This backgrounder provides information on GLORIATM -AF registry
Read more >
This backgrounder is about the link between AF and ischaemic stroke
Read more >
This backgrounder is about the largest and most extensive survey ever conducted in patients diagnosed with AF and physicians who treat the condition
Read more >
Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis
Read more >
BI submits first oncology compound, afatinib* for European approval
Read more >
Released on 27.08.2012
Read more >
Summary, Checklist & Glossary
Read more >
This infographic shows how atrial fibrillation leads to stroke
Read more >
This infographic shows the common drug interaction associated with Vitamin K Antagonists (VKAs)
Read more >
Interview with Prof James-Chih-Hsin Yang Director of the Cancer Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan
Read more >
Pivotal study on afatinib may challenge standard first line treatment
Read more >
Interview with Dr Vera Hirsh Associate Professor, McGill University Department of Medical Oncology Royal Victoria Hospital, Montreal, Canada
Read more >
Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA
Read more >
Interview with Prof Tony Shu Kam Mok, MD Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
Read more >
Interview with Prof James-Chih-Hsin Yang Director of the Cancer Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan
Read more >
Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA
Read more >
Media Alert: Pivotal Phase III Results for Afatinib to be Presented at ASCO 2012
Read more >
In this video, Prof. Gregory Lip introduces the GLORIATM AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting.
Read more >
In this video, Professor Gregory Lip talks about GLORIATM – AF registry program and explains how important it is to run a truly patient registry
Read more >
In this video, Professor Gregory Lip talks about the GLORIATM - AF registry program and its importance in light of the introduction of multiple novel oral anticoagulants
Read more >
In this video, Professor Gregory Lip talks about the GLORIATM -AF registry program and why obtaining real-world data is so important
Read more >
BI moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*
Read more >
Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA
Read more >
Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA
Read more >
Interview with Jonathan Ledermann, BSc, MD, FRCP Cancer Research UK and UCL Cancer Institute London, UK
Read more >
Interview with Ken Swenerton, MD, FRCPC Cancer Medicine in Gynecology Clinical Professor, Faculty of Medicine, University of British Columbia
Read more >
Interview with Professor Ignace Vergote Chairman of the Leuven Cancer Institute
Read more >
Interview with Ken Swenerton, MD, FRCPC Cancer Medicine in Gynecology Clinical Professor, Faculty of Medicine, University of British Columbia
Read more >
Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center
Read more >
Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center
Read more >
Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center
Read more >
BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events
Read more >
Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*
Read more >
This factsheet provides information on atrial fibrillation (AF)
Read more >
New subgroup analysis of the LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients likely to have EGFR mutations
Read more >
Interview with Marianne Nicolson, MD, FRCP Consultant Medical Oncologist, Aberdeen Royal Infirmary, Aberdeen, Scotland
Read more >
Interview with John Heymach, MD, PhD Associate Professor, MD Anderson Cancer Center, Houston, Texas, USA
Read more >
Interview with Kathleen Pritchard, MD, FRCPC Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
Read more >
Interview with David Ross Camidge, MD, PhD Assistant Professor, University of Colorado, Denver, Colorado, USA
Read more >
Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients
Read more >
Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer
Read more >
This infographic shows the prevalence of atrial fibrillation (AF) in the United States and Europe
Read more >
This infographic demonstrates that the hospital admissions caused by atrial fibrillation (AF) rose 60% in the past 20 years
Read more >
This infographic demonstrates how atrial fibrillation (AF) affects the heart
Read more >
This infographic demonstrates the mode of action of DTIs
Read more >
This infographic shows the personal burden of atrial fibrillation (AF)related strokes
Read more >
This infographic lists the common risk factors for atrial fibrillation (AF)
Read more >
This infographic shows the most common causes of venous thromboembolism (VTE)
Read more >
This infographic demonstrates the symptoms of venous thromboembolism (VTE)
Read more >
This infographic shows what VTE is. Deep vein thrombosis and pulmonary embolism
Read more >
BI's lead investigational oncology compound BIBW 2992* demonstrates...
Read more >
Volasertib* (compound code BI 6727) is an investigational, potent, and selective inhibitor in vitro of PLK1, an important regulator of the cell cycle.
Read more >
Boehringer Ingelheim initiates first Phase III clinical trial in Ovarian Cancer
Read more >
Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer
Read more >
Boehringer Ingelheim and DxS sign agreement for a companion diagnostic test to identify EGFR mutations in patients with lung cancer
Read more >
Boehringer Ingelheim to Present New Phase II Clinical Data on two Lead Oncology Compounds at ASCO 2009
Read more >
First pivotal trials begin for Boehringer Ingelheim’s novel triple angiokinase inhibitor BIBF 1120*
Read more >
Data suggests promising overall survival and progression-free survival with BIBF 1120*
Read more >
New data on BIBW 2992*, a potent, irreversible, second-generation oral signal transduction inhibitor provides glimpse of next chapter in lung cancer care
Read more >
BI accesses field of oncology with three compounds in phase II
Read more >
